(2025年第11周), 医药生物 板块整体表现优于市场,细分领域中, 医药商业 板块以6.44%的涨幅领跑。在银屑病治疗领域,国产TYK2抑制剂研发进展成为焦点。 诺诚健华 宣布其自主研发的新型TYK2抑制剂ICP-488进入III期注册临床试验,而 益方生物 的D-2570在II期临床中展现出优于同类产品的潜力。随着美国皮肤病学会年会(AAD)上多项自免疾病数据的披露,TYK2抑制剂的临床价值...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.